{"id":419968,"date":"2021-01-25T07:03:15","date_gmt":"2021-01-25T12:03:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=419968"},"modified":"2021-01-25T07:03:15","modified_gmt":"2021-01-25T12:03:15","slug":"faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/","title":{"rendered":"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fazemed.com%2F&amp;esheet=52366432&amp;newsitemid=20210125005156&amp;lan=en-US&amp;anchor=Faze+Medicines&amp;index=1&amp;md5=3630384290c0eb0a59df1147dae585fb\">Faze Medicines<\/a>, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., as its chief executive officer (CEO). Dr. Vickers previously served as president and CEO of Northern Biologics and has worked in a diverse array of senior leadership roles across biotech and leading pharma companies.\n<\/p>\n<p>\nDr. Vickers takes the helm of Faze shortly after the company launched in December 2020 with an $81 million Series A financing. In addition to his role as CEO, Dr. Vickers will also join Faze\u2019s board of directors.\n<\/p>\n<p>\n\u201cWe are excited that Phil is joining Faze as CEO as he brings a broad set of leadership experiences in research and development across the biotech and pharma industry, including successfully driving programs from idea to market in rare diseases and multiple other therapeutic areas and across different therapeutic modalities,\u201d said Cary Pfeffer, M.D., chairman of the board of directors and partner at Third Rock Ventures. \u201cPhil\u2019s vast leadership experience, as well as his passion for translating cutting-edge areas of science into novel therapeutics, makes him the ideal leader for Faze as we press forward in our ambitious mission to change the way diseases related to alterations in biomolecular condensates are targeted and treated.\u201d\n<\/p>\n<p>\nResearchers at Faze are harnessing the power of biomolecular condensates, membrane-less clusters of molecules that dynamically organize to perform a wide array of cell functions, to advance potential breakthrough therapies. Under Dr. Vickers\u2019 leadership, Faze will advance its product engine to systematically understand and exploit biomolecular condensate biology to treat severe diseases across many different areas, with an initial focus on amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1).\n<\/p>\n<p>\n\u201cThe work Faze is pioneering is new and exciting, and also rooted in strong foundational research that represents an incredible opportunity to provide benefit to patients,\u201d Dr. Vickers said. \u201cBiomolecular condensate behavior is linked to numerous neurological diseases where there is a high medical need, including ALS, and I look forward to leading and innovating as part of the team at Faze as we work to transform treatment of these and other serious disorders.\u201d\n<\/p>\n<p>\nDr. Vickers has over 30 years of experience as a researcher and leader in the pharmaceutical industry. He most recently served as president and CEO of Northern Biologics, Inc., a company developing first-in-class therapeutic antibodies targeting the tumor microenvironment. Preclinical and clinical programs at Northern Biologics were acquired by big pharma companies in 2020. Prior to his time at Northern Biologics, Dr. Vickers served as global head of research and development at Shire Pharmaceuticals, where he was a member of the executive leadership team. His breadth of experience includes leading roles at multiple global biotech and pharma companies, including Merck, Pfizer, Boehringer Ingelheim and Resolvyx Pharmaceuticals, where he led teams in the development and approval of innovative small molecule and biologic therapeutics to treat diseases in a wide range of therapeutic areas. Dr. Vickers currently serves on the board of Revance Therapeutics, a company developing aesthetic and therapeutic agents based on novel delivery technologies for the neurotoxic protein botulinum toxin, and AVROBIO, a company developing lentiviral gene therapies to treat rare diseases. He earned his B.Sc. in applied biochemistry from the University of Salford in Manchester, England and his Ph.D. in biochemistry from the University of Toronto in Ontario, Canada.\n<\/p>\n<p><b>About Faze Medicines<\/b><\/p>\n<p>\nFaze Medicines is a biotechnology company harnessing the groundbreaking new science of biomolecular condensates to create medical breakthroughs. Faze was founded by renowned scientific leaders in the field of biomolecular condensates and is supported by a world-class syndicate of investors including Third Rock Ventures, Novartis Venture Fund, Eli Lilly and Company, AbbVie Ventures, Invus, Catalio Capital Management, Casdin Capital and Alexandria Venture Investments. For more information, visit fazemed.com.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210125005156\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210125005156\/en\/<\/a><\/span><\/p>\n<p>\nGwen Schanker<br \/>\n<br \/>Ten Bridge Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:gwen@tenbridgecommunications.com\">gwen@tenbridgecommunications.com<br \/>\n<\/a><br \/>(269)-921-3607\n<\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210125005156\/en\/854062\/3\/Faze_logo_RGB_%281%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., as its chief executive officer (CEO). Dr. Vickers previously served as president and CEO of Northern Biologics and has worked in a diverse array of senior leadership roles across biotech and leading pharma companies. Dr. Vickers takes the helm of Faze shortly after the company launched in December 2020 with an $81 million Series A financing. In addition to his role as CEO, Dr. Vickers will also join Faze\u2019s board of directors. \u201cWe are excited that Phil is joining Faze as &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-419968","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., as its chief executive officer (CEO). Dr. Vickers previously served as president and CEO of Northern Biologics and has worked in a diverse array of senior leadership roles across biotech and leading pharma companies. Dr. Vickers takes the helm of Faze shortly after the company launched in December 2020 with an $81 million Series A financing. In addition to his role as CEO, Dr. Vickers will also join Faze\u2019s board of directors. \u201cWe are excited that Phil is joining Faze as &hellip; Continue reading &quot;Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-25T12:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer\",\"datePublished\":\"2021-01-25T12:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/\"},\"wordCount\":699,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/\",\"name\":\"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-25T12:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer - Market Newsdesk","og_description":"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Faze Medicines, a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., as its chief executive officer (CEO). Dr. Vickers previously served as president and CEO of Northern Biologics and has worked in a diverse array of senior leadership roles across biotech and leading pharma companies. Dr. Vickers takes the helm of Faze shortly after the company launched in December 2020 with an $81 million Series A financing. In addition to his role as CEO, Dr. Vickers will also join Faze\u2019s board of directors. \u201cWe are excited that Phil is joining Faze as &hellip; Continue reading \"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-25T12:03:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer","datePublished":"2021-01-25T12:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/"},"wordCount":699,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/","name":"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-25T12:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210125005156r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/faze-medicines-appoints-biotech-leader-philip-vickers-ph-d-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=419968"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/419968\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=419968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=419968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=419968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}